PRZOOM - /newswire/ -
Tucson, AZ, United States, 2012/02/14 - HTG Molecular Diagnostics, a provider of products for gene expression profiling for clinical research, companion diagnostic and prognostic applications in oncology recently added three professionals to its executive team - HTGmolecular.com.
HTG Molecular, a privately-held, Tucson-based provider of molecular-technology solutions, added three industry-renown professionals to its executive team: Shaun McMeans, Vice President of Finance, Administration and Chief Financial Officer; Timothy J Holtzer, Ph.D., M.A., Vice President of Clinical Diagnostic Development; and Sam Rua, Vice President of Regulatory Affairs and Quality Systems.
Shaun McMeans, Vice President of Finance, Administration and Chief Financial Officer, joined HTG Molecular in February, 2012, and leads the organization’s finance and administration groups. Immediately prior to joining HTG Molecular, Mr. McMeans served as the CFO for Securaplane Technologies in Tucson. McMeans’ extensive experience includes positions as CFO of The Long Companies, interim CFO with Fluoresco and Inter-Fab, and as the CFO and COO of LXU Healthcare, Inc. Mr. McMeans moved to Tucson in 2000 from Lancaster, Pennsylvania where he enjoyed a twelve-year career in finance at Burnham Corporation. Mr McMeans earned a B.S. in Accounting from Penn State University.
Timothy J. Holtzer, Ph.D., M.A., Vice President of Clinical Diagnostic Development, joined HTG Molecular in January, 2012, and leads clinical diagnostic development. Prior to joining HTG Molecular, Dr. Holtzer dedicated over 25 years of his career to diagnostic development in large and small diagnostic companies in the US and Canada. Dr. Holtzer directed diagnostic teams at DiagnoCure, and Centocor, Cancer Genetics as well as leading cross-functional teams at Abbott Laboratories and the Whitehead Institute. Dr Holtzer received his B.A. from the University of Minnesota, his M.A. from Mankato State University and his Ph.D. from the University of Illinois at Chicago.
Sam Rua, Vice President of Regulatory Affairs and Quality Systems, joined HTG Molecular in November, 2011, and directs the quality systems organization and global regulatory initiatives. Prior to joining HTG, Mr. Rua served in a variety of quality and regulatory roles with increasing responsibilities, most recently with Ventana Medical Systems, a member of the Roche Diagnostics Group. Mr. Rua has successfully led applications for PMA approvals and clearances for multiple IVD and companion diagnostic tests. Mr. Rua’s career includes positions as VP of Global Regulatory and Clinical Affairs at Beckman Coulter, and Executive Director of Quality and Regulatory at Third Wave Technologies, Inc. (now Hologic), where he led the regulatory and clinical strategies for the Invader® UGT1A1 test and the Invader® HPV test. Mr. Rua received his B.S. in Microbiology from the University of Arizona.
About HTG Molecular Diagnostics
HTG Molecular Diagnostics (htgmolecular.com) is a privately-held, Tucson-based company providing products for gene expression profiling, miRNA, siRNA and mRNA measurement for clinical research, companion diagnostic and prognostic applications in oncology. The company’s qNPA molecular technology platform is well-suited for reliably detecting changes in gene expression levels especially from formalin-fixed, paraffin-embedded (FFPE) tissue.